Albert Pares

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4987711/publications.pdf

Version: 2024-02-01

343 papers	19,167 citations	15880 67 h-index	14779 131 g-index
375 all docs	375 docs citations	375 times ranked	12299 citing authors

#	Article	IF	Citations
1	The EASLâ€“Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality. Lancet, The, 2022, 399, 61-116.	6.3	257
2	Machine learning in primary biliary cholangitis: A novel approach for risk stratification. Liver International, 2022, 42, 615-627.	1.9	7
3	Noninvasive Prediction of Outcomes in Autoimmune Hepatitisâ€“Related Cirrhosis. Hepatology Communications, 2022, 6, 1392-1402.	2.0	5
4	Risk factors and outcomes associated with recurrent autoimmune hepatitis following liver transplantation. Journal of Hepatology, 2022, 77, 84-97.	1.8	21
5	Liver stiffness measurement by vibration-controlled transient elastography improves outcome prediction in primary biliary cholangitis. Journal of Hepatology, 2022, 77, 1545-1553.	1.8	33
6	Bilirubin increases viability and decreases osteoclast apoptosis contributing to osteoporosis in advanced liver diseases. Bone, 2022, 162, 116483.	1.4	8
7	Measurement of Gamma Glutamyl Transferase to Determine Risk of Liver Transplantation or Death in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2021, 19, 1688-1697.e14.	2.4	30
8	Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: AÂDouble-Blind, Randomized, Placebo-Controlled Trial. Gastroenterology, 2021, 160, 734-743.e6.	0.6	82
9	Obeticholic acid is associated with improvements in AST-to-platelet ratio index and GLOBE score in patients with primary biliary cholangitis. JHEP Reports, 2021, 3, 100191.	2.6	10
10	A placebo-controlled randomised trial of budesonide for PBC following an insufficient response to UDCA. Journal of Hepatology, 2021, 74, 321-329.	1.8	55
11	Clustering Reveals the Prognostic Role of Serum Albumin Values Within the Normal Range in Patients with Primary Biliary Cholangitis. Digestive and Liver Disease, 2021, 53, S5.	0.4	1
12	A Comparison of Prognostic Scores (Mayo, UK-PBC, and GLOBE) in Primary Biliary Cholangitis. American Journal of Gastroenterology, 2021, 116, 1514-1522.	0.2	14
13	Obeticholic Acid and Fibrates in Primary Biliary Cholangitis: Comparative Effects in a Multicentric Observational Study. American Journal of Gastroenterology, 2021, 116, 2250-2257.	0.2	14
14	A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA. Journal of Hepatology, 2021, 74, 1344-1354.	1.8	77
15	Quality of life in patients with primary biliary cholangitis: A cross-geographical comparison. Journal of Translational Autoimmunity, 2021, 4, 100081.	2.0	7
16	Combination of fibrates with obeticholic acid is able to normalise biochemical liver tests in patients with difficultâ€toâ€treat primary biliary cholangitis. Alimentary Pharmacology and Therapeutics, 2021, 53, 1138-1146.	1.9	37
17	Practical management of primary biliary cholangitis. Revista Espanola De Enfermedades Digestivas, 2021, , .	0.1	2
18	Response to Granito et al.. American Journal of Gastroenterology, 2021, 116, 217-217.	0.2	0

#	Article	IF	Citations
19	Factors Associated With Progression and Outcomes of Early Stage Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 684-692.e6.	2.4	17
20	Bile acids and bilirubin effects on osteoblastic gene profile. Implications in the pathogenesis of osteoporosis in liver diseases. Gene, 2020, 725, 144167.	1.0	17
21	Long-Term Obeticholic Acid Therapy Improves Histological Endpoints in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2020, 18, 1170-1178.e6.	2.4	61
22	Higher seroprevalence of hepatitis E virus in autoimmune hepatitis: Role of falseâ€positive antibodies. Liver International, 2020, 40, 558-564.	1.9	10
23	Novel Antiâ€“Hexokinase 1 Antibodies Are Associated With Poor Prognosis in Patients With Primary Biliary Cholangitis. American Journal of Gastroenterology, 2020, 115, 1634-1641.	0.2	21
24	Bilirubin and bile acids in osteocytes and bone tissue. Potential role in the cholestaticâ€induced osteoporosis. Liver International, 2020, 40, 2767-2775.	1.9	13
25	Reduction and stabilization of bilirubin with obeticholic acid treatment in patients with primary biliary cholangitis. Liver International, 2020, 40, 1121-1129.	1.9	15
26	Goals of Treatment for Improved Survival in Primary Biliary Cholangitis: Treatment Target Should Be Bilirubin Within the Normal Range and Normalization of Alkaline Phosphatase. American Journal of Gastroenterology, 2020, 115, 1066-1074.	0.2	74
27	Serum gamma-glutamyltransferase is a prognostic biomarker in primary biliary cholangitis and improves risk stratification based on alkaline phosphatase. Digestive and Liver Disease, 2020, 52, e4-e5.	0.4	0
28	Long-term impact of preventive UDCA therapy after transplantation for primary biliary cholangitis. Journal of Hepatology, 2020, 73, 559-565.	1.8	47
29	Number needed to treat with ursodeoxycholic acid therapy to prevent liver transplantation or death in primary biliary cholangitis. Gut, 2020, 69, 1502-1509.	6.1	28
30	Simplified care-pathway selection for nonspecialist practice. European Journal of Gastroenterology and Hepatology, 2020, Publish Ahead of Print, .	0.8	2
31	EASL Clinical Practice Guidelines on nutrition in chronic liver disease. Journal of Hepatology, 2019, 70, 172-193.	1.8	608
32	FRI-021-Comparing the predictive performance of the Mayo risk score and the GLOBE score in a large cohort of patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e392-e393.	1.8	0
33	Fibrosis stage is an independent predictor of outcome in primary biliary cholangitis despite biochemical treatment response. Alimentary Pharmacology and Therapeutics, 2019, 50, 1127-1136.	1.9	66
34	FRI-033-Long-term obeticholic acid treatment is associated with improvements in collagen morphometry in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 70, e398.	1.8	0
35	GS-18-Preventive administration of ursodeoxycholic acid after liver transplantation for primary biliary cholangitis prevents disease recurrence and prolongs graft survival. Journal of Hepatology, 2019, 70, e84.	1.8	4
36	Presentation and Outcomes of Pregnancy in Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2819-2821.	2.4	24

#	Article	IF	Citations
37	Promoter hypermethylation of the AE2/SLC4A2 gene in PBC. JHEP Reports, 2019, 1, 145-153.	2.6	14
38	Suppression of a broad spectrum of liver autoimmune pathologies by single peptide-MHC-based nanomedicines. Nature Communications, 2019, 10, 2150.	5.8	73
39	Three years of obeticholic Acid (OCA) therapy results in histological improvements in patients with primary biliary cholangitis: further analysis of the POISE Biopsy substudy. Digestive and Liver Disease, 2019, 51, e19.	0.4	2
40	The Prevalence of Anti-Hexokinase-1 and Anti-Kelch-Like 12 Peptide Antibodies in Patients With Primary Biliary Cholangitis Is Similar in Europe and North America: A Large International, Multi-Center Study. Frontiers in Immunology, 2019, 10, 662.	2.2	21
41	FRI-046-Raising awareness and messaging risk in patients with primary biliary cholangitis: The rapid Global PBC Screening Test. Journal of Hepatology, 2019, 70, e404.	1.8	1
42	Effects of Age and Sex of Response to Ursodeoxycholic Acid and Transplant-free Survival in Patients With Primary Biliary Cholangitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2076-2084.e2.	2.4	54
43	Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis. Journal of Hepatology, 2019, 71, 357-365.	1.8	148
44	ATU-09â€...Obeticholic acid treatment is associated with improved collagen morphometry in patients with primary biliary cholangitis. , 2019, , .		0
45	Factors Associated With Recurrence of Primary Biliary Cholangitis After Liver Transplantation and Effects on Graft and Patient Survival. Gastroenterology, 2019, 156, 96-107.e1.	0.6	82
46	Osteoporosis in chronic liver disease. Liver International, 2018, 38, 776-785.	1.9	79
47	Colangitis biliar primaria. Medicina ClÃnica, 2018, 151, 242-249.	0.3	14
48	A worldwide cross-ethnic study of quality of life in patients with PBC: Attitude or latitude?. Digestive and Liver Disease, 2018, 50, 26.	0.4	1
49	A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology, 2018, 67, 1890-1902.	3.6	204
50	Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response. American Journal of Gastroenterology, 2018, 113, 49-55.	0.2	94
51	Major Hepatic Complications in Ursodeoxycholic Acid-Treated Patients With Primary Biliary Cholangitis: Risk Factors and Time Trends in Incidence and Outcome. American Journal of Gastroenterology, 2018, 113, 254-264.	0.2	64
52	Milder disease stage in patients with primary biliary cholangitis over a 44â€year period: A changing natural history. Hepatology, 2018, 67, 1920-1930.	3.6	55
53	Genetic association analysis identifies variants associated with disease progression in primary sclerosing cholangitis. Gut, 2018, 67, 1517-1524.	6.1	42
54	PWE-080â€...Change in bilirubin with obeticholic acid in primary biliary cholangitis patients with high baseline bilirubin. , 2018, , .		0

#	Article	IF	Citations
55	Primary biliary cholangitis in Spain. Results of a Delphi study of epidemiology, diagnosis, follow-up and treatment. Revista Espanola De Enfermedades Digestivas, 2018, 110, 641-649.	0.1	3
56	Hepatobiliary and non-hepatobiliary malignancies in PSC patients from Southern Europe: a comparative study in two European centers. Digestive and Liver Disease, 2018, 50, e354.	0.4	0
57	Results of a randomised controlled trial of budesonide add-on therapy in patients with primary biliary cholangitis and an incomplete response to ursodeoxycholic acid. Journal of Hepatology, 2018, 68, S38.	1.8	11
58	Ursodeoxycholic acid treatment is associated with prolonged transplant-free survival in primary biliary cholangitis â€“ even in patients without biochemical improvements. Journal of Hepatology, 2018, 68, S8.	1.8	7
59	Long-Term Obeticholic Acid (OCA) treatment associated with reversal or stabilization of fibrosis/cirrhosis in patients with Primary Biliary Cholangitis (PBC). Journal of Hepatology, 2018, 68, S111-S112.	1.8	5
60	Primary biliary cholangitis and bone disease. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 63-70.	1.0	13
61	Primary biliary cholangitis in Spain: fewer symptoms and milder disease at presentation, but similar therapeutic response over the years. Journal of Hepatology, 2018, 68, S218-S219.	1.8	0
62	Histologic stage is a stronger predictor of transplant free survival than APRI and FIB-4 in patients with primary biliary cholangitis. Journal of Hepatology, 2018, 68, S219-S220.	1.8	0
63	Younger age is associated with lower transplant-free survival relative to a general population in patients with Primary Biliary Cholangitis. Journal of Hepatology, 2018, 68, S222-S223.	1.8	0
64	Stratification of hepatocellular carcinoma risk using the GLOBE score in patients with primary biliary cholangitisâ€“ the Global PBC Study Group. Journal of Hepatology, 2018, 68, S229-S230.	1.8	0
65	Change in bilirubin with obeticholic acid treatment in primary biliary cholangitis patients with high baseline bilirubin: a retrospective analysis of POISE, 201, and 202. Journal of Hepatology, 2018, 68, S232.	1.8	0
66	Pregnancy and autoimmune hepatitis: presentation and outcomes. Journal of Hepatology, 2018, 68, S233.	1.8	1
67	A dose-response relationship in the association between ursodeoxycholic acid treatment and prolonged transplant-free survival in primary biliary cholangitis. Journal of Hepatology, 2018, 68, S230.	1.8	0
68	Primary sclerosing cholangitis response to the combination of fibrates with ursodeoxycholic acid: Frenchâ€“Spanish experience. Clinics and Research in Hepatology and Gastroenterology, 2018, 42, 521-528.	0.7	40
69	Primary biliary cholangitis. Medicina ClÃnica (English Edition), 2018, 151, 242-249.	0.1	4
70	SAT0068â€…Bilirubin promotes down-regulation of runx2 and up-regulation of rankl gene expression in bone explants and in osteoblastic and osteocytic cell lines. , 2018, , .		0
71	Novel Treatment Strategies for Primary Biliary Cholangitis. Seminars in Liver Disease, 2017, 37, 060-072.	1.8	7
72	Enhanced liver fibrosis test predicts transplantâ€free survival in primary sclerosing cholangitis, a multiâ€centre study. Liver International, 2017, 37, 1554-1561.	1.9	54

#	Article	IF	Citations
73	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. Gastroenterology, 2017, 152, 1975-1984.e8.	0.6	355
74	An appealing new agent for treating cholestatic pruritus. Lancet, The, 2017, 389, 1078-1080.	6.3	0
75	The novel hexokinase 1 antibodies are useful for the diagnosis and associated with bad prognosis in primary biliary cholangitis. Journal of Hepatology, 2017, 66, S355-S356.	1.8	5
76	Early predictive factors of corticosteroids response in patients with severe/acute or fulminant autoimmune hepatitis. Journal of Hepatology, 2017, 66, S549.	1.8	0
77	Efficacy and Safety of Mycophenolate Mofetil and Tacrolimus as Second-line Therapy for Patients With Autoimmune Hepatitis. Clinical Gastroenterology and Hepatology, 2017, 15, 1950-1956.e1.	2.4	84
78	Juan RodÃ©s. A successful and extraordinary life of a visionary hepatologist. Gut, 2017, 66, 736-736.	6.1	0
79	Expert clinical management of autoimmune hepatitis in the real world. Alimentary Pharmacology and Therapeutics, 2017, 45, 723-732.	1.9	66
80	Genome-wide association study of primary sclerosing cholangitis identifies new risk loci and quantifies the genetic relationship with inflammatory bowel disease. Nature Genetics, 2017, 49, 269-273.	9.4	230
81	Effect of obeticholic acid treatment in patients with primary biliary cholangitis on categorical shifts in GLOBE score. Journal of Hepatology, 2017, 66, S106.	1.8	0
82	Increase in age at diagnosis of Primary Biliary Cholangitis over the last 40 years. Journal of Hepatology, 2017, 66, S358.	1.8	0
83	Low platelet count influences the performance of the different biochemical criteria of ursodeoxycholic acid therapy response in primary biliary cholangitis. Journal of Hepatology, 2017, 66, S355.	1.8	4
84	Advances in treatment options for patients with primary biliary cholangitis. Expert Opinion on Orphan Drugs, 2017, 5, 847-857.	0.5	0
85	Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial. Trials, 2017, 18, 230.	0.7	28
86	The GLOBE score identifies PBC patients at increased risk of liver transplantation or death in different age-categories over time. Journal of Hepatology, 2017, 66, S543-S544.	1.8	8
87	Thyroid Dysfunction in Primary Biliary Cholangitis: A Comparative Study at Two European Centers. American Journal of Gastroenterology, 2017, 112, 114-119.	0.2	34
88	FRI0573â€…Osteocytes are involved in the pathogenesis of osteoporosis in chronic cholestasis. effects of bilirubin and bile acids on osteocytic cell lines. , 2017, , .		0
89	Effect of Obeticholic Acid Treatment in Patients With Primary Biliary Cholangitis on Categorical Shifts in GLOBE Score. American Journal of Gastroenterology, 2017, 112, S495.	0.2	0
90	Sclerostin Expression in Bile Ducts of Patients With Chronic Cholestasis May Influence the Bone Disease in Primary Biliary Cirrhosis. Journal of Bone and Mineral Research, 2016, 31, 1725-1733.	3.1	27

#	Article	IF	Citations
91	Bezafibrate Alleviates Pruritus and Decreases Specific Circulating Metabolites in Patients with Primary Biliary Cholangitis. Journal of Hepatology, 2016, 64, S429.	1.8	2
92	The ALT/AST Ratio and Total Protein Level Identify the Autoimmune Etiology in Patients with Fulminant Hepatitis. Journal of Hepatology, 2016, 64, S429-S430.	1.8	0
93	Behavioral Patterns of Total Serum Bilirubin Prior to Major Clinical Endpoints in 3529 Patients with Primary Biliary Cholangitis. Journal of Hepatology, 2016, 64, S633-S634.	1.8	3
94	Genotype-Phenotype Analysis across 130,422 Genetic Variants Identifies Rspo3 as the First Genome-Wide Significant Modifier Gene in Primary Sclerosing Cholangitis. Journal of Hepatology, 2016, 64, S642-S643.	1.8	1
95	Ursodeoxycholic Acid Modulates the Effects of Lithocholic Acid and Bilirubin on the Gene Expression Profiling in Osteoblastic Cells. Journal of Hepatology, 2016, 64, S648.	1.8	0
96	Enteroendocrine cells are a potential source of serum autotaxin in men. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2016, 1862, 696-704.	1.8	12
97	Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut, 2016, 65, 321-329.	6.1	139
98	Risk stratification in autoimmune cholestatic liver diseases: Opportunities for clinicians and trialists. Hepatology, 2016, 63, 644-659.	3.6	57
99	P1177 : Risk factors for hepatic decompensation in primary biliary cirrhosis - results of an international follow up study of 2326 patients. Journal of Hepatology, 2015, 62, S795.	1.8	0
100	P1180 : Identification of pbc patients in need of additional therapy during the course of UDCA treatment -an international multicenter study. Journal of Hepatology, 2015, 62, S796-S797.	1.8	1
101	P1184 : Age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis. Journal of Hepatology, 2015, 62, S798-S799.	1.8	10
102	PWE-096ÂNon-invasive assessment of disease severity in primary sclerosing cholangitis (psc): clinical scores, transient elastography (te) and the enhanced liver fibrosis (elf) test: Abstract PWE-096 Table 1. Gut, 2015, 64, A254.1-A254.	6.1	0
103	Histone deacetylase 4 promotes cholestatic liver injury in the absence of prohibitinâ€1. Hepatology, 2015, 62, 1237-1248.	3.6	34
104	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Hepatology, 2015, 62, 1620-1622.	3.6	125
105	Enhanced liver fibrosis score predicts transplantâ€free survival in primary sclerosing cholangitis. Hepatology, 2015, 62, 188-197.	3.6	106
106	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Clinics and Research in Hepatology and Gastroenterology, 2015, 39, e57-e59.	0.7	36
107	Preface. Digestive Diseases, 2015, 33, 1-1.	0.8	0
108	Therapy of Primary Biliary Cirrhosis: Novel Approaches for Patients with Suboptimal Response to Ursodeoxycholic Acid. Digestive Diseases, 2015, 33, 125-133.	0.8	9

#	Article	IF	Citations
109	TRAIL-producing NK cells contribute to liver injury and related fibrogenesis in the context of GNMT deficiency. Laboratory Investigation, 2015, 95, 223-236.	1.7	29
110	Efficacy of Obeticholic Acid in Patients With Primary Biliary Cirrhosis and Inadequate Response to Ursodeoxycholic Acid. Gastroenterology, 2015, 148, 751-761.e8.	0.6	470
111	Extrahepatic Malignancies in Primary Biliary Cirrhosis: A Comparative Study at Two European Centers. Clinical Reviews in Allergy and Immunology, 2015, 48, 254-262.	2.9	19
112	P1147 : Validation of an alkaline phosphatase and bilirubin response criterion as biomarker for transplant-free survival in primary biliary cirrhosis in the world's two largest cohorts. Journal of Hepatology, 2015, 62, S782-S783.	1.8	0
113	P1155 : FXR Agonism with obeticholic acid may attenuate bone mineral density decrease in subjects with primary biliary cirrhosis. Journal of Hepatology, 2015, 62, S786.	1.8	3
114	P1159 : Identification of serum metabolites associated with cholestatic pruritus. Journal of Hepatology, 2015, 62, S787-S788.	1.8	0
115	P1201 : Long-term therapy with bezafibrate and ursodeoxycholic acid is insufficient for preventing disease progression in patients with advanced primary biliary cirrhosis. Journal of Hepatology, 2015, 62, S806.	1.8	3
116	P1207 : Fatigue in primary biliary cirrhosis: similar prevalence to the population from the same geographic area, and association with comorbidities and severity of cholestasis. Journal of Hepatology, 2015, 62, S809.	1.8	0
117	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. American Journal of Gastroenterology, 2015, 110, 1536-1538.	0.2	30
118	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Digestive and Liver Disease, 2015, 47, 924-926.	0.4	15
119	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. Gastroenterology, 2015, 149, 1627-1629.	0.6	96
120	Changing Nomenclature for PBC: From â€˜Cirrhosisâ€™ to â€˜Cholangitisâ€™. Clinical Gastroenterology and Hepatology, 2015, 13, 1867-1869.	2.4	16
121	Development and Validation of a Scoring System to Predict Outcomes of Patients With Primary Biliary Cirrhosis Receiving Ursodeoxycholic Acid Therapy. Gastroenterology, 2015, 149, 1804-1812.e4.	0.6	330
122	Changing nomenclature for PBC: From â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Journal of Hepatology, 2015, 63, 1285-1287.	1.8	85
123	Changing nomenclature for PBC: from â€˜cirrhosisâ€™ to â€˜cholangitisâ€™. Gut, 2015, 64, 1671-1672.	6.1	28
124	Bone Disease in Patients with Cirrhosis. , 2015, , 295-305.		0
125	OC-030â€…Effective Stratification Of Hepatocellular Carcinoma Risk In Primary Biliary Cirrhosis: Results Of A Multi-centre International Study. Gut, 2014, 63, A15-A16.	6.1	0
126	Old and Novel Therapies for Primary Biliary Cirrhosis. Seminars in Liver Disease, 2014, 34, 341-351.	1.8	22

#	Article	IF	Citations
127	Treatment of primary biliary cirrhosis: Is there more to offer than ursodeoxycholic acid?. Clinical Liver Disease, 2014, 3, 29-33.	1.0	9
128	Levels of Alkaline Phosphatase and Bilirubin Are Surrogate End Points of Outcomes of Patients With Primary Biliary Cirrhosis: An International Follow-up Study. Gastroenterology, 2014, 147, 1338-1349.e5.	0.6	365
129	Ursodeoxycholic acid decreases bilirubinâ€induced osteoblast apoptosis. European Journal of Clinical Investigation, 2014, 44, 1206-1214.	1.7	26
130	Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver International, 2014, 34, 197-203.	1.9	94
131	O5 PRIMARY SCLEROSING CHOLANGITIS FROM A GLOBAL PERSPECTIVE â€“ A MULTICENTER, RETROSPECTIVE, OBSERVATIONAL STUDY OF THE INTERNATIONAL PSC STUDY GROUP. Journal of Hepatology, 2014, 60, S3.	1.8	3
132	P347 INCIDENCE AND RISK FACTORS FOR EXTRA-HEPATIC MALIGNANCIES (EM) IN PRIMARY BILIARY CIRRHOSIS: A COMPARATIVE STUDY FROM TWO EUROPEAN REFERRAL CENTERS. Journal of Hepatology, 2014, 60, S182-S183.	1.8	0
133	O132 EFFECTIVE STRATIFICATION OF HEPATOCELLULAR CARCINOMA RISK IN PRIMARY BILIARY CIRRHOSIS: RESULTS OF A MULTI-CENTRE INTERNATIONAL STUDY. Journal of Hepatology, 2014, 60, S55.	1.8	3
134	P463 PHB1 PROTECTIVE ROLE IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2014, 60, S223.	1.8	0
135	P374 LONG-TERM TREATMENT OF PRIMARY BILIARY CIRRHOSIS WITH THE FXR AGONIST OBETICHOLIC ACID SHOWS DURABLE EFFICACY. Journal of Hepatology, 2014, 60, S192-S193.	1.8	2
136	P372 APOPTOSIS INDUCED BY BILIRUBIN AND LITHOCHOLIC ACID IN HUMAN OSTEOBLASTS IS NEUTRALIZED BY URSODEOXYCHOLIC ACID. Journal of Hepatology, 2014, 60, S192.	1.8	0
137	P373 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS. EFFECTS OF ALBUMIN DIALYSIS. Journal of Hepatology, 2014, 60, S192.	1.8	1
138	Incidence and risk factors for extra-hepatic malignancies in primary biliary cirrhosis: A comparative study from two European referral centers. Digestive and Liver Disease, 2014, 46, e29.	0.4	0
139	Extracorporeal liver support in severe alcoholic hepatitis. World Journal of Gastroenterology, 2014, 20, 8011.	1.4	10
140	Randomized trial comparing monthly ibandronate and weekly alendronate for osteoporosis in patients with primary biliary cirrhosis. Hepatology, 2013, 58, 2070-2078.	3.6	81
141	930 DECREASE OF LIVER STIFFNESS IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND BIOCHEMICAL RESPONSE TO URSODEOXYCHOLIC ACID. Journal of Hepatology, 2013, 58, S384.	1.8	0
142	950 PROGNOSIS OF PRIMARY BILIARY CIRRHOSIS WITH FEATURES OF AUTOIMMUNE HEPATITIS OVERLAP SYNDROME. ROLE OF URSODEOXYCHOLIC ACID IN LONG-TERM SURVIVAL. Journal of Hepatology, 2013, 58, S391.	1.8	0
143	941 ALKALINE PHOSPHATASE VALUES ARE A SURROGATE MARKER IN PREDICTION OF TRANSPLANT FREE SURVIVAL IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS â€“ AN INTERNATIONAL, COLLABORATIVE ANALYSIS. Journal of Hepatology, 2013, 58, S388.	1.8	0
144	Soil Organic Carbon is Increased in Mixed-Species Plantations of Eucalyptus and Nitrogen-Fixing Acacia. Ecosystems, 2013, 16, 123-132.	1.6	82

#	Article	IF	Citations
145	Extracorporeal albumin dialysis with the molecular adsorbent recirculating system in acute-on-chronic liver failure: The RELIEF trial. Hepatology, 2013, 57, 1153-1162.	3.6	452
146	Dense genotyping of immune-related disease regions identifies nine new risk loci for primary sclerosing cholangitis. Nature Genetics, 2013, 45, 670-675.	9.4	339
147	Ursodeoxycholic acid increases differentiation and mineralization and neutralizes the damaging effects of bilirubin on osteoblastic cells. Liver International, 2013, 33, 1029-1038.	1.9	27
148	Hepatotoxicity associated with glucosamine and chondroitin sulfate in patients with chronic liver disease. World Journal of Gastroenterology, 2013, 19, 5381.	1.4	22
149	Sex Differences Associated with Primary Biliary Cirrhosis. Clinical and Developmental Immunology, 2012, 2012, 1-11.	3.3	37
150	Tuberculosis Is Not a Risk Factor for Primary Biliary Cirrhosis: A Review of the Literature. Tuberculosis Research and Treatment, 2012, 2012, 1-10.	0.2	2
151	38 SERUM METABOLOMIC PROFILING IN PATIENTS WITH CHOLESTATIC PRURITUS. Journal of Hepatology, 2012, 56, S17.	1.8	0
152	952 LONG-TERM (LT) THERAPY OF A FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) MAINTAINS BIOCHEMICAL RESPONSE IN PRIMARY BILIARY CIRRHOSIS (PBC). Journal of Hepatology, 2012, 56, S372.	1.8	3
153	964 THE FARNESOID X RECEPTOR (FXR) AGONIST OBETICHOLIC ACID (OCA) INCREASES PLASMA FGF-19 CONCENTRATIONS AND DECREASES BILE ACID SYNTHESIS IN PRIMARY BILIARY CIRRHOSIS (PBC). Journal of Hepatology, 2012, 56, S377.	1.8	8
154	970 SERUM AUTOTAXIN ACTIVITY IS ASSOCIATED WITH PRURITUS AND DISEASE DURATION AND SEVERITY IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2012, 56, S379-S380.	1.8	0
155	Patients with cirrhosis and ascites have false values of bone density. Osteoporosis International, 2012, 23, 1481-1487.	1.3	28
156	Role for mycobacterial infection in pathogenesis of primary biliary cirrhosis?. World Journal of Gastroenterology, 2012, 18, 4855.	1.4	11
157	1306 URSODEOXYCHOLIC ACID NEUTRALIZES THE NOXIOUS EFFECTS OF LITHOCHOLIC ACID AND BILIRUBIN ON OSTEOBLASTS. Journal of Hepatology, 2011, 54, S515.	1.8	0
158	1299 PROMISING EFFECTS OF BEZAFIBRATE IN PATIENTS WITH PRIMARY BILIARY CIRRHOSIS AND INCOMPLETE RESPONSE TO URSODEOXYCHOLIC ACID. Journal of Hepatology, 2011, 54, S512.	1.8	0
159	Management of osteoporosis in liver disease. Clinics and Research in Hepatology and Gastroenterology, 2011, 35, 438-445.	0.7	44
160	28 AN INTERNATIONAL STUDY EVALUATING THE FARNESOID X RECEPTOR AGONIST OBETICHOLIC ACID AS MONOTHERAPY IN PBC. Journal of Hepatology, 2011, 54, S13.	1.8	52
161	Proteomic Analysis of Polypeptides Captured from Blood during Extracorporeal Albumin Dialysis in Patients with Cholestasis and Resistant Pruritus. PLoS ONE, 2011, 6, e21850.	1.1	14
162	Effects of bilirubin and sera from jaundiced patients on osteoblasts: Contribution to the development of osteoporosis in liver diseases. Hepatology, 2011, 54, 2104-2113.	3.6	61

#	Article	IF	Citations
163	OP02 The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC. Gut, 2011, 60, A50-A50.	6.1	9
164	Usability Evaluation of the Interactive Personal Patient Profile-Prostate Decision Support System With African American Men. Journal of the National Medical Association, 2010, 102, 290-302.	0.6	10
165	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine, 2010, 37, 180-186.	1.1	14
166	The effect of the alendronate on OPG/RANKL system in differentiated primary human osteoblasts. Endocrine, 2010, 37, 322-328.	1.1	15
167	Reply:. Hepatology, 2010, 52, 2239-2239.	3.6	1
168	Characterization of peptides and proteins in commercial HSA solutions. Proteomics, 2010, 10, 172-181.	1.3	22
169	Lithocholic acid downregulates vitamin D effects in human osteoblasts. European Journal of Clinical Investigation, 2010, 40, 25-34.	1.7	57
170	Low Bone Mass and Severity of Cholestasis Affect Fracture Risk in Patients With Primary Biliary Cirrhosis. Gastroenterology, 2010, 138, 2348-2356.	0.6	115
171	Treatment of resistant pruritus from cholestasis with albumin dialysis: Combined analysis of patients from three centers. Journal of Hepatology, 2010, 53, 307-312.	1.8	104
172	Liver and bone. Archives of Biochemistry and Biophysics, 2010, 503, 84-94.	1.4	58
173	2 FARNESOID-X RECEPTOR AGONISTS: A NEW CLASS OF DRUGS FOR THE TREATMENT OF PBC? AN INTERNATIONAL STUDY EVALUATING THE ADDITION OF INT-747 TO URSODEOXYCHOLIC ACID. Journal of Hepatology, 2010, 52, S1-S2.	1.8	56
174	184 MONTHLY IBANDRONATE VS. WEEKLY ALENDRONATE IN THE TREATMENT OF OSTEOPOROSIS ASSOCIATED WITH PRIMARY BILIARY CIRRHOSIS: SIMILAR EFFICACY BUT DIFFERENT ADHERENCE. Journal of Hepatology, 2010, 52, S79.	1.8	6
175	535 HIGH BILIRUBIN REDUCES CELL SURVIVAL AND DIFFERENTIATION OF PRIMARY HUMAN OSTEOBLASTS. IS THIS EFFECT APPLICABLE TO THE SERUM OF CHRONIC CHOLESTATIC PATIENTS?. Journal of Hepatology, 2010, 52, S214-S215.	1.8	3
176	849 PATIENTS WITH ASCITES HAVE FALSE VALUES OF BONE MINERAL DENSITY AT THE CENTRAL SKELETON. A PROSPECTIVE STUDY. Journal of Hepatology, 2010, 52, S331.	1.8	2
177	Psicosis y diferencias sociales: Comparando la prevalencia de las psicosis en dos medios urbanos diferenciados. Revista De La AsociaciÃ³n EspaÃ±ola De NeuropsiquiatrÃa, 2010, 30, .	0.1	0
178	New ELISA for Detecting Primary Biliary Cirrhosisâ€“Specific Antimitochondrial Antibodies. Clinical Chemistry, 2009, 55, 978-985.	1.5	71
179	Incidence, risk factors, and survival of hepatocellular carcinoma in primary biliary cirrhosis: Comparative analysis from two centers. Hepatology, 2009, 50, 1162-1168.	3.6	93
180	High osteoprotegerin serum levels in primary biliary cirrhosis are associated with disease severity but not with the mRNA gene expression in liver tissue. Journal of Bone and Mineral Metabolism, 2009, 27, 347-354.	1.3	19

#	Article	IF	Citations
181	Albumin dialysis improves hepatic encephalopathy and decreases circulating phenolic aromatic amino acids in patients with alcoholic hepatitis and severe liver failure. Critical Care, 2009, 13, R8.	2.5	40
182	Risk factors for fracture and osteopenia in primary biliary cirrhosis. Bone, 2009, 44, S387.	1.4	0
183	Lithocholic acid decreases cell survival and downregulates the effects of vitamin d3 on primary human osteoblasts. Bone, 2009, 44, S319-S320.	1.4	0
184	EASL Clinical Practice Guidelines: Management of cholestatic liver diseases. Journal of Hepatology, 2009, 51, 237-267.	1.8	1,540
185	Neighborhood differences in psychoses: Prevalence of psychotic disorders in two socially-differentiated metropolitan areas of Barcelona. Schizophrenia Research, 2009, 112, 143-148.	1.1	14
186	61 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS. COMPARATIVE ANALYSIS FROM TWO EUROPEAN REFERRAL CENTERS. Journal of Hepatology, 2009, 50, S26.	1.8	1
187	106 IDENTIFICATION OF AN EXTREMELY BENIGN ASYMPTOMATIC PRESENTATION IN A LARGE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2009, 50, S44.	1.8	0
188	662 CHARACTERIZATION OF PEPTIDES AND PROTEINS CAPTURED BY THE MARS SYSTEM IN PATIENTS WITH CHOLESTASIS AND RESISTANT PRURITUS. Journal of Hepatology, 2009, 50, S243.	1.8	0
189	Excellent long-term survival in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. , 2009, , 259-269.		1
190	Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology, 2008, 48, 169-176.	3.6	1,553
191	123 PRESENTATION AND NATURAL HISTORY OF PRIMARY BILIARY CIRRHOSIS IN SPAIN: EXPERIENCE OVER 35 YEARS. Journal of Hepatology, 2008, 48, S54.	1.8	1
192	874 INCIDENCE AND RISK FACTORS FOR HEPATOCELLULAR CARCINOMA IN PRIMARY BILIARY CIRRHOSIS. Journal of Hepatology, 2008, 48, S328.	1.8	1
193	Osteoporosis in Primary Biliary Cirrhosis: Pathogenesis and Treatment. Clinics in Liver Disease, 2008, 12, 407-424.	1.0	61
194	[674] PRESENTATION, COURSE, AND OUTCOME OF A SINGLE-CENTRE COHORT OF PATIENTS WITH PRIMARY BILIARY CIRRHOSIS: CHANGES THROUGH THREE DECADES. Journal of Hepatology, 2007, 46, S255.	1.8	0
195	Anti-gp210 antibody mirrors disease severity in primary biliary cirrhosis. Hepatology, 2007, 45, 1583-1583.	3.6	51
196	Serum paraoxonase-1 in chronic alcoholics: Relationship with liver disease. Clinical Biochemistry, 2007, 40, 645-650.	0.8	55
197	641 A study of primary biliary cirrhosis specific antinuclear antibodies in predicting disease severity and outcome. Journal of Hepatology, 2006, 44, S238.	1.8	0
198	646 Once-weekly compared with daily alendronate for low bone mass in women with primary biliary cirrhosis. Journal of Hepatology, 2006, 44, S239-S240.	1.8	0

#	Article	IF	Citations
199	Excellent Long-Term Survival in Patients With Primary Biliary Cirrhosis and Biochemical Response to Ursodeoxycholic Acid. Gastroenterology, 2006, 130, 715-720.	0.6	649
200	Treatment of bone disorders in liver disease. Journal of Hepatology, 2006, 45, 445-453.	1.8	48
201	Gene polymorphisms as predictors of decreased bone mineral density and osteoporosis in primary biliary cirrhosis. European Journal of Gastroenterology and Hepatology, 2005, 17, 311-315.	0.8	38
202	Antimitochondrial antibodies in patients with chronic hepatitis C virus infection: description of 18 cases and review of the literature. Journal of Viral Hepatitis, 2005, 12, 648-654.	1.0	27
203	Prevalence and Mechanisms of Hyperhomocysteinemia in Chronic Alcoholics. Alcoholism: Clinical and Experimental Research, 2005, 29, 1044-1048.	1.4	54
204	Prevalence and clinical significance of isotype specific antinuclear antibodies in primary biliary cirrhosis. Gut, 2005, 54, 528-532.	6.1	123
205	Severity of cholestasis and advanced histological stage but not menopausal status are the major risk factors for osteoporosis in primary biliary cirrhosis. Journal of Hepatology, 2005, 42, 573-577.	1.8	163
206	Extracorporeal Albumin Dialysis: A Procedure for Prolonged Relief of Intractable Pruritus in Patients with Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2004, 99, 1105-1110.	0.2	111
207	Serum Immunological Profile in Patients with Chronic Autoimmune Cholestasis. American Journal of Gastroenterology, 2004, 99, 2150-2157.	0.2	21
208	Primary Biliary Cirrhosis Specific Antinuclear Antibodies in Patients from Spain. American Journal of Gastroenterology, 2004, 99, 763-764.	0.2	28
209	Disease-specific cross-reactivity between mimicking peptides of heat shock protein of mycobacterium gordonae and dominant epitope of E2 subunit of pyruvate dehydrogenase is common in Spanish but not British patients with primary biliary cirrhosis. Journal of Autoimmunity, 2004, 22, 353-362.	3.0	64
210	A randomized placebo controlled trial of vitamin E for alcoholic hepatitis. Journal of Hepatology, 2004, 40, 40-46.	1.8	152
211	Tratamiento de las complicaciones Ã³seas. GastroenterologÃa Y HepatologÃa, 2004, 27, 45-51.	0.2	0
212	Alendronate is more effective than etidronate for increasing bone mass in osteopenic patients with primary biliary cirrhosis. American Journal of Gastroenterology, 2003, 98, 2268-2274.	0.2	24
213	Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. Journal of Hepatology, 2003, 39, 12-16.	1.8	199
214	Blood levels of antioxidant vitamins in alcoholic liver disease. Relationship to liver damage. Journal of Hepatology, 2003, 38, 191.	1.8	0
215	Improvement in systemic hemodynamics after albumin dialysis is associated with a decrease in vasoactive agents. Journal of Hepatology, 2003, 38, 67.	1.8	1
216	Albumin dialysis decreases aromatic amino acids and improves hepatic encephalopathy in patients with severe liver dysfunction. Journal of Hepatology, 2003, 38, 67.	1.8	1

#	Article	IF	Citations
217	Natural history of primary biliary cirrhosis. Clinics in Liver Disease, 2003, 7, 779-794.	1.0	80
218	Alendronate Is More Effective Than Etidronate for Increasing Bone Mass in Osteopenic Patients With Primary Biliary Cirrhosis. American Journal of Gastroenterology, 2003, 98, 2268-2274.	0.2	96
219	Cholangiocarcinoma in Primary Sclerosing Cholangitis: Risk Factors and Clinical Presentation. Scandinavian Journal of Gastroenterology, 2002, 37, 1205-1211.	0.6	280
220	Genetic polymorphisms of alcohol metabolizing enzymes do not influence the development of alcoholic liver disease. Journal of Hepatology, 2002, 36, 143.	1.8	0
221	Hyperhomocysteinemia in chronic alcoholism. Relationship to liver damage. Journal of Hepatology, 2002, 36, 143-144.	1.8	1
222	The molecular adsorbent recirculating system (MARS) improves systemic hemodynamics and hepatic encephalopathy in patients with severe alcoholic hepatitis. Journal of Hepatology, 2002, 36, 150.	1.8	2
223	Duration and severity of the disease but not menopausal status are the main risk factors for osteoporosis in primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 154-155.	1.8	7
224	Molecular adsorbent recirculating system: a new procedure for relieving intractable pruritus in patients with primary biliary cirrhosis. Journal of Hepatology, 2002, 36, 155.	1.8	3
225	Expected developments in hepatology. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2002, 16, 957-970.	1.0	6
226	Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitis. Hepatology, 2002, 35, 652-657.	3.6	77
227	Hepatocellular carcinoma in primary biliary cirrhosis: similar incidence to that in hepatitis C virusâ€“related cirrhosis. American Journal of Gastroenterology, 2001, 96, 1160-1163.	0.2	26
228	Cross-reactivity between mycobacterium gordonae and PDC-E2, the major target of anti-mitochondrial antibody, is present in Spanish but not British patients with PBC. Journal of Hepatology, 2001, 34, 19.	1.8	3
229	Long-term ursodeoxycholic acid treatment delays progression of mild primary biliary cirrhosis. Journal of Hepatology, 2001, 34, 187-188.	1.8	6
230	Factors influencing histological progression of early primary biliary cirrhosis. Effect of ursodeoxycholic acid. Journal of Hepatology, 2001, 34, 189-190.	1.8	7
231	Influence of the genetic polymorphism of collagen type I A2 in the development of alcoholic cirrhosis. Journal of Hepatology, 2001, 34, 200.	1.8	0
232	Association of the tumour necrosis factor alpha -308 but not the interleukin 10 -627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut, 2001, 49, 288-294.	6.1	97
233	Collagen type Iα1 and vitamin D receptor gene polymorphisms and bone mass in primary biliary cirrhosis. Hepatology, 2001, 33, 554-560.	3.6	64
234	Hepatocellular Carcinoma in Primary Biliary Cirrhosis: Similar Incidence To That in Hepatitis C Virusâ€“Related Cirrhosis. American Journal of Gastroenterology, 2001, 96, 1160-1163.	0.2	96

#	Article	IF	Citations
235	The HLA-DR3,DQ2 Heterozygous Genotype is Associated with an Accelerated Progression of Primary Sclerosing Cholangitis. Scandinavian Journal of Gastroenterology, 2001, 36, 886-890.	0.6	61
236	Alendronate versus etidronate for osteopenic patients with primary biliary cirrhosis: results after two years of treatment. Journal of Hepatology, 2001, 34, 19.	1.8	3
237	S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. Clinical Science, 2000, 99, 315-320.	1.8	12
238	S-Adenosylmethionine prevents hepatic tocopherol depletion in carbon tetrachloride-injured rats. Clinical Science, 2000, 99, 315.	1.8	7
239	Short- and long-term outcome of severe alcohol-induced hepatitis treated with steroids or enteral nutrition: A multicenter randomized trial. Hepatology, 2000, 32, 36-42.	3.6	329
240	Enhanced DNA Binding and Activation of Transcription Factors NF-Î¹B and AP-1 by Acetaldehyde in HEPG2 Cells. Journal of Biological Chemistry, 2000, 275, 14684-14690.	1.6	55
241	Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 528-536.	1.8	29
242	Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. Journal of Hepatology, 2000, 32, 561-566.	1.8	254
243	Cholangiocarcinoma in primary sclerosing cholangitis: K-ras mutations and Tp53 dysfunction are implicated in the neoplastic development. Journal of Hepatology, 2000, 32, 374-380.	1.8	79
244	Natural history of primary sclerosing cholangitis. A longterm follow-up study of 394 european primary sclerosing cholangitis patients. Journal of Hepatology, 2000, 32, 32.	1.8	136
245	Time dependent neural network prognostic model for Primary Sclerosing Cholangitis (PSC). Journal of Hepatology, 2000, 32, 207.	1.8	0
246	New time dependent prognostic models for Primary Sclerosing Cholangitis (PSC). Journal of Hepatology, 2000, 32, 207.	1.8	0
247	Age, obesity and hyperglycemia but not ethanol intake are the main risk factors for developing fatty liver in men. Journal of Hepatology, 2000, 32, 210.	1.8	1
248	Antibodies against the COOH-terminal region of E. coli ClpP protease in patients with primary biliary cirrhosis. Journal of Hepatology, 2000, 33, 528-536.	1.8	36
249	HLA class II haplotypes in primary sclerosing cholangitis patients from five European populations. Tissue Antigens, 1999, 53, 459-469.	1.0	151
250	High Bilirubin Levels Interfere with Serum Tartrate-Resistant Acid Phosphatase Determination: Relevance as a Marker of Bone Resorption in Jaundiced Patients. Calcified Tissue International, 1999, 64, 301-303.	1.5	8
251	Differential role of ethanol and acetaldehyde in the induction of oxidative stress in HEP G2 cells: Effect on transcription factors AP-1 and NF-Î¹B. Hepatology, 1999, 30, 1473-1480.	3.6	82
252	S-Adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial. Journal of Hepatology, 1999, 30, 1081-1089.	1.8	428

#	Article	IF	Citations
253	Hepatic Fibrogenic Activity in Chronic Alcoholic Pancreatitis. Pancreas, 1999, 19, 276-280.	0.5	3
254	Synthesis and Degradation of Collagen in Pancreatic Fibrogenesis. Pancreas, 1999, 18, 34-38.	0.5	7
255	Collagen-Related Markers of Bone Turnover Reflect the Severity of Liver Fibrosis in Patients with Primary Biliary Cirrhosis. Journal of Bone and Mineral Research, 1998, 13, 731-738.	3.1	82
256	Metadoxine accelerates fatty liver recovery in alcoholic patients: results of a randomized double-blind, placebo-control trial. Journal of Hepatology, 1998, 28, 54-60.	1.8	68
257	Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter trial. Journal of Hepatology, 1998, 28, 615-621.	1.8	289
258	The role of metalloproteinases in CCl4 induced fibrosis. Influence of zinc administration. Journal of Hepatology, 1998, 28, 86.	1.8	0
259	Vitamin D receptor gene polymorphism and bone mass in primary biliary cirrhosis. Journal of Hepatology, 1998, 28, 140.	1.8	1
260	Circulating metalloproteinases and their tissue inhibitors in alcoholic liver disease. Relationship to liver fibrosis. Journal of Hepatology, 1998, 28, 173.	1.8	0
261	Serum markers of fibrogenesis and collagenolysis in patients with chronic liver disease. Journal of Hepatology, 1998, 28, 174.	1.8	0
262	Hepatitis G virus infection in chronic liver disease. Gut, 1998, 42, 107-111.	6.1	38
263	Etidronate versus fluoride for treatment of osteopenia in primary biliary cirrhosis: Preliminary results after 2 years. Gastroenterology, 1997, 113, 219-224.	0.6	93
264	Carbohydrate-Deficient Transferrin as a Marker of Alcohol Consumption in Male Patients with Liver Disease. Alcoholism: Clinical and Experimental Research, 1997, 21, 923-927.	1.4	23
265	Zinc Administration Improves Gastric Alcohol Dehydrogenase Activity and First-Pass Metabolism of Ethanol in Alcohol-Fed Rats. Alcoholism: Clinical and Experimental Research, 1997, 21, 1619-1622.	1.4	9
266	Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. European Journal of Clinical Investigation, 1997, 27, 667-672.	1.7	59
267	Effects of ethanol feeding and malnutrition on collagen synthesizing and degrading enzymes in rat pancreas. Alcohol, 1996, 13, 227-231.	0.8	1
268	Effects of S-adenosylmethionine on lipid peroxidation and liver fibrogenesis in carbon tetrachloride-induced cirrhosis. Journal of Hepatology, 1996, 25, 200-205.	1.8	111
269	Mycobacteria - related to the aetiopathogenesis of primary biliary cirrhosis?. Journal of Hepatology, 1996, 24, 125.	1.8	4
270	Serum Amino-Terminal Propeptide of Type III Procollagen Levels in Chronic Pancreatitis. Pancreas, 1996, 12, 153-158.	0.5	2

#	Article	IF	Citations
271	FRAXA premutation associated with premature ovarian failure. , 1996, 64, 373-375.		54
272	Effects of prolonged ethanol intake and malnutrition on rat pancreas.. Gut, 1996, 38, 285-292.	6.1	25
273	Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology, 1996, 24, 1399-1403.	3.6	27
274	Vertebral fractures and osteopenia in chronic alcoholic patients. Calcified Tissue International, 1995, 57, 111-114.	1.5	60
275	An unexpected transformation by reaction of congested Î±-(o-nitrophenyl) ketones with tris (dimethylamino) methane. A new heterocyclic system: 6,1. Tetrahedron, 1994, 50, 9769-9774.	1.0	9
276	Acetaldehyde activates the promoter of the mouse Î±2(I) collagen gene. Hepatology, 1994, 19, 498-503.	3.6	32
277	Fibrogenic and collagenolytic activity in carbon-tetrachloride-injured rats: beneficial effects of zinc administration. Journal of Hepatology, 1994, 21, 292-298.	1.8	43
278	Mycobacterium gordonae DNA in liver tissue of patients with primary biliary cirrhosis. Journal of Hepatology, 1994, 21, S87.	1.8	6
279	Pentoxifylline prevents liver fibrosis but induces cellular damage in carbon tetrachloride injured rats. Journal of Hepatology, 1994, 21, S136.	1.8	3
280	Cross-reactivity of anti-Mycobacterium gordonae antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. Journal of Hepatology, 1994, 21, 673-677.	1.8	90
281	Cyclosporin A increases the biochemical markers of bone remodeling in primary biliary cirrhosis. Journal of Hepatology, 1994, 21, 24-28.	1.8	36
282	Epidemiology of primary sclerosing cholangitis in Spain. Journal of Hepatology, 1994, 21, 787-791.	1.8	153
283	Disulfiram-induced hepatitis. Report of four cases and review of the literature. Journal of Hepatology, 1994, 21, 853-857.	1.8	55
284	Role of Zinc in the Process of Pancreatic Fibrosis in Chronic Alcoholic Pancreatitis. Pancreas, 1994, 9, 270-274.	0.5	8
285	Bone mass improves in alcoholics after 2 years of abstinence. Journal of Bone and Mineral Research, 1994, 9, 1607-1612.	3.1	54
286	Acetaldehyde activates the promoter of the mouse $alpha;2(I) collagen gene*1. Hepatology, 1994, 19, 498-503.	3.6	33
287	Protective effect of S-adenosyl-L-methionine (SAMe) in the development of CCl4-induced cirrhosis. Hepatology, 1994, 19, I47.	3.6	0
288	Drinking in the Injury Event: A Comparison of Emergency Room Populations in the United States, Mexico, and Spain. Substance Use and Misuse, 1993, 28, 931-945.	0.6	21

#	Article	IF	Citations
289	Determinants of Ethanol and Acetaldehyde Metabolism in Chronic Alcoholics. Alcoholism: Clinical and Experimental Research, 1993, 17, 48-53.	1.4	33
290	Prediction of alcohol-related casualties in the emergency room: a U.S.-Spain comparison.. Journal of Studies on Alcohol and Drugs, 1993, 54, 308-314.	2.4	10
291	Activation of the mouse $alpha;2(I) collagen gene promoter by acetaldehyde. Hepatology, 1993, 18, A152.	3.6	0
292	Relationship between hepatic lipid peroxidation and fibrogenesis in carbon tetrachloride-treated rats: effect of zinc administration. Clinical Science, 1992, 83, 695-700.	1.8	72
293	Effects of long-term rifampicin administration in primary biliary cirrhosis. Gastroenterology, 1992, 102, 2077-2080.	0.6	227
294	Validity of self-reported alcohol consumption in the emergency room: data from the United States, Mexico and Spain.. Journal of Studies on Alcohol and Drugs, 1992, 53, 203-207.	2.4	50
295	Sodium fluoride prevents bone loss in primary biliary cirrhosis. Journal of Hepatology, 1992, 15, 345-349.	1.8	67
296	Influence of dietary zinc on hepatic collagen and prolyl hydroxylase activity in alcoholic rats. Hepatology, 1992, 16, 815-819.	3.6	17
297	S-adenosylmethionine treatment prevents carbon tetrachlorideâ€”inducedS-adenosylmethionine synthetase inactivation and attenuates liver injury. Hepatology, 1992, 16, 1022-1027.	3.6	156
298	Drinking patterns and problems: a comparison of emergency room populations in the United States and Spain. Drug and Alcohol Dependence, 1991, 29, 5-15.	1.6	13
299	Protective effect of zinc on hepatic lipid peroxidation and fibrogenesis in CCL4-treated rats. A possible role for metallothioneins. Journal of Hepatology, 1991, 13, S16.	1.8	0
300	Effects of S-adenosylmethicnine on liver fibrosis in rats. Journal of Hepatology, 1991, 13, S124.	1.8	1
301	A prognestic index (PI) for patient selection and timing of liver transplantation in cirrhosis with ascites. Journal of Hepatology, 1991, 13, S32.	1.8	0
302	A simple method for assessing timing of liver transplantation in primary biliary cirrhosis (PBC). Journal of Hepatology, 1991, 13, S124.	1.8	2
303	Quantitative measurement of fibrosis in pancreatic tissue. International Journal of Gastrointestinal Cancer, 1991, 10, 23-29.	0.4	19
304	Effect of parenteral amino acid supplementation on short-term and long-term outcomes in severe alcoholic hepatitis: A randomized controlled trial. Hepatology, 1991, 14, 1090-1096.	3.6	105
305	Are hepatitis C virus antibodies involved in chronic liver diseases other than non-A, non-B hepatitis?. Hepatology, 1991, 14, 1303-1304.	3.6	1
306	Hepatitis C virus antibodies in chronic alcoholic patients: Association with severity of liver injury. Hepatology, 1990, 12, 1295-1299.	3.6	242

#	Article	IF	Citations
307	Hepatitis C Virus Infection in Patients with Nonalcoholic Chronic Liver Disease. Annals of Internal Medicine, 1990, 112, 921.	2.0	94
308	Influence of dietary zinc on hepatic collagen and prolyl-hydroxylase activity in alcoholic rats. Journal of Hepatology, 1990, 11, S26.	1.8	0
309	Rifampicin versus phenobarbital for treatment of pruritus in primary biliary cirrhosis. Results of a crossover randomized trial. Journal of Hepatology, 1990, 10, P3.	1.8	0
310	Effects of zinc on hepatic lipid peroxidation and liver fibrosis in carbon tetrachloride-treated rats. Journal of Hepatology, 1990, 11, S14.	1.8	2
311	Liver diseases associated with autoantibodies directed to nuclear envelope components. Hepatology, 1989, 9, 911-912.	3.6	2
312	COMPARISON OF RIFAMPICIN WITH PHENOBARBITONE FOR TREATMENT OF PRURITUS IN BILIARY CIRRHOSIS. Lancet, The, 1989, 333, 574-576.	6.3	207
313	Influence of abstinence on serum procollagen type III peptide levels in alcoholic liver disease. Journal of Hepatology, 1989, 9, S133.	1.8	0
314	Low bone mineral density in primary biliary cirrhosis. Influence of intestinal calcium absorption and bone formation. Journal of Hepatology, 1989, 9, S159.	1.8	0
315	Fibrogenesis and collagenolysis in rats induced to liver cirrhosis. Journal of Hepatology, 1989, 9, S102.	1.8	0
316	Effects of long-term rifampicin administration in primary biliary cirrhosis. Journal of Hepatology, 1989, 9, S105.	1.8	0
317	Effects of zinc administration on liver fibrogenesis and collagenolysis in rats induced to cirrhosis. Journal of Hepatology, 1989, 9, S36.	1.8	1
318	Association between the histocompatibility antigens and the severity of alcoholic liver disease. Journal of Hepatology, 1989, 9, S133.	1.8	0
319	Influence of liver disease on hepatic alcohol and aldehyde dehydrogenases. Gastroenterology, 1989, 97, 708-714.	0.6	57
320	Alcoholic foamy degeneration in Spain. Prevalence and clinicoâ€pathological features. Liver, 1989, 9, 79-85.	0.1	21
321	Comparative study of aminoglycoside nephrotoxicity in normal rats and rats with experimental cirrhosis. Hepatology, 1988, 8, 837-844.	3.6	11
322	Autoantibodies against nuclear envelope-associated proteins in primary biliary cirrhosis. Hepatology, 1988, 8, 930-938.	3.6	101
323	Esophageal dysfunction in primary biliary cirrhosis. Journal of Hepatology, 1988, 7, 362-367.	1.8	8
324	Effects of zinc on liver fibrosis and vitamin a metabolism in rats. Journal of Hepatology, 1988, 7, S4.	1.8	3

#	Article	IF	Citations
325	Analysis of factors predicting early seroconversion to anti-HBe in HBeAg-positive chronic hepatitis B. Journal of Hepatology, 1988, 6, 15-22.	1.8	16
326	URINE ETHANOL ASSESSMENT: A HELPFUL METHOD FOR CONTROLLING ABSTINENCE IN ALCOHOLIC LIVER DISEASE. Alcohol and Alcoholism, 1988, 23, 403-407.	0.9	5
327	Portal hypertension in primary biliary cirrhosis. Journal of Hepatology, 1987, 5, 292-298.	1.8	96
328	Histological course of alcoholic hepatitis. Journal of Hepatology, 1986, 2, 33-42.	1.8	271
329	Nuclear lamina antibodies in primary biliary cirrhosis. Journal of Hepatology, 1986, 3, S28.	1.8	2
330	Serum procollagen type III peptide as a marker of hepatic fibrogenesis in alcoholic hepatitis. Gastroenterology, 1986, 90, 1241-1246.	0.6	94
331	Lymphocytotoxic antibodies in primary biliary cirrhosis. Digestive Diseases and Sciences, 1985, 30, 829-833.	1.1	11
332	Measurement of fibrosis in needle liver biopsies: Evaluation of a colorimetric method. Hepatology, 1985, 5, 815-818.	3.6	125
333	Serum procollagen type III peptide does not reflect hepatic collagen content in alcoholics with inactive cirrhosis. Journal of Hepatology, 1985, 1, S252.	1.8	2
334	Synoptic Effects on the Local Winds in Todos Santos Bay: A Case Study. Monthly Weather Review, 1983, 111, 1494-1500.	0.5	4
335	Acute Thallium Poisoning: An Evaluation of Different Forms of Treatment. Journal of Toxicology: Clinical Toxicology, 1982, 19, 1015-1021.	1.5	11
336	Renal tubular acidosis in primary biliary cirrhosis. Gastroenterology, 1981, 80, 681-686.	0.6	61
337	Pulmonary involvement in primary biliary cirrhosis.. Thorax, 1981, 36, 208-212.	2.7	48
338	Nonoliguric acute renal failure in an intensive care unit. Intensive Care Medicine, 1980, 6, 244-245.	3.9	1
339	Renal Tubular Function in Chronic Cholestasis. , 1979, , 132-136.		0
340	Primary Sclerosing Cholangitis. Southern Medical Journal, 1978, 71, 855-856.	0.3	1
341	Financial Goals and Debt Ratio Determinants: A Survey of Practice in Five Countries. Financial Management, 1975, 4, 27.	1.5	60
342	Ursodeoxycholic acid protects osteoblastic cells from bilirubin and lithocholic acid induced apoptosis. Bone Abstracts, 0, , .	0.0	0

#	Article	IF	Citations
343	Gene expression profiling of osteoblastic cells cultured with lithocholic acid or bilirubin. Implications in the pathogenesis of osteoporosis in liver diseases. Bone Abstracts, 0, , .	0.0	0